Patents matching “formulation”

US 11690898

Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic formulations comprising the same

BIOMARIN PHARMACEUTICAL INC. · Granted Jul 4, 2023 · Expires Jun 29, 2043

US 11690826

Methods for treating demodex blepharitis using lotilaner formulations

Tarsus Pharmaceuticals, Inc. · Granted Jul 4, 2023 · Expires Jun 29, 2043

US 11690827

Methods for treating ocular Demodex using lotilaner formulations

Tarsus Pharmaceuticals, Inc. · Granted Jul 4, 2023 · Expires Jun 29, 2043

US 11684614

Formulations of hydroxypyridonate actinide/lanthanide decorporation agents

The Regents of the University of California · Granted Jun 27, 2023 · Expires Jun 22, 2043

US 11679079

Ophthalmic formulations and related methods

ETERNATEAR, INC. · Granted Jun 20, 2023 · Expires Jun 15, 2043

US 11679078

Ophthalmic formulations and related methods

ETERNATEAR, INC. · Granted Jun 20, 2023 · Expires Jun 15, 2043

US 11673967

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Jun 13, 2023 · Expires Jun 8, 2043

US 11672863

Enhanced solubility drug-containing formulations

United Therapeutics Corporation · Granted Jun 13, 2023 · Expires Jun 8, 2043

US 11667702

Stable aqueous formulations of aflibercept

Coherus BioSciences, Inc. · Granted Jun 6, 2023 · Expires Jun 1, 2043

US 11654124

Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives

AMNEAL PHARMACEUTICALS LLC · Granted May 23, 2023 · Expires May 18, 2043

US 11648211

Nanoencapsulated combination drug formulations

Northwestern University · Granted May 16, 2023 · Expires May 11, 2043

US 11649207

Formulations of T-type calcium channel modulators and methods of use thereof

PRAXIS PRECISION MEDICINES, INC. · Granted May 16, 2023 · Expires May 11, 2043

US 11642398

Factor IX polypeptide formulations

BIOVERATIV THERAPEUTICS INC. · Granted May 9, 2023 · Expires May 4, 2043

US 11633361

Soft chew pharmaceutical formulations

First Time US Generics LLC · Granted Apr 25, 2023 · Expires Apr 20, 2043

US 11633416

Oral formulations of CD73 compounds

Arcus Biosciences, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

US 11633405

Steroid hormone pharmaceutical formulations

Compass Therapeutics LLC · Granted Apr 25, 2023 · Expires Apr 20, 2043

US 11629159

Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

Compass Pathfinder Limited · Granted Apr 18, 2023 · Expires Apr 13, 2043

US 11617793

Anhydrous sodium thiosulfate and formulations thereof

Fennec Pharmaceuticals, Inc. · Granted Apr 4, 2023 · Expires Mar 30, 2043

US 11603407

Stable antibody formulation

REGENERON PHARMACEUTICALS, INC. · Granted Mar 14, 2023 · Expires Mar 9, 2043

US 11596690

Stabilized formulations containing anti-IL-33 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Mar 7, 2023 · Expires Mar 2, 2043

US 11590205

Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents

XERIS PHARMACEUTICALS, INC. · Granted Feb 28, 2023 · Expires Feb 23, 2043

US 11583540

Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

Windtree Therapeutics, Inc. · Granted Feb 21, 2023 · Expires Feb 16, 2043

US 11583563

Adeno-associated virus formulations

Takeda Pharmaceutical Company Limited · Granted Feb 21, 2023 · Expires Feb 16, 2043

US 11576871

Formulations of cysteamine and cystamine

The Regents of the University of California · Granted Feb 14, 2023 · Expires Feb 9, 2043